...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Free
Message: Happy Thanksgiving all....

Personally speaking, i'm quite interested in the anti-inflammatory properties and the  QOL questionnaire data that is coming.  I have to take all CAD patient off NSAIDs, regardless of arthritis and other debilitating inflammatory conditions.   If RVX208 turns out to be an anti-inflammatory that does not worsen heart disease, potentially improves it...  big win. 

If it did noting else (which I do not  believe), a safe (RX or OTC) anti-inflammatory  for heart disease patients would be quite valuable, all IMO. 

Anxiously awaiting AHA like everyone here, read every post, and appreciating the commentary  as we wait... sometimes wildly informative, othertimes good for a chuckle.  Thanks to all, GLTA.

Share
New Message
Please login to post a reply